Eli Lilly Commits $27 Billion to U.S. Plants and Agrees to Buy Kelonia for $7 Billion

Eli Lilly and Company (NYSE:LLY) is expanding its domestic production footprint with a commitment of at least $27 billion for U.S. manufacturing facilities, including four planned sites across Alabama, Virginia, and Texas. Alongside the factory expansion, the drugmaker reached an agreement to acquire Kelonia Therapeutics for up to $7 billion, securing an in vivo CAR-T platform and an early-stage program for multiple myeloma.

The strategic moves come as the pharmaceutical firm experiences strong demand across its treatments. The company reached a market capitalization of approximately $1.056 trillion, placing it among the most valuable global corporations. Wall Street price targets have moved higher, supported by expectations that weight-loss medication Zepbound will exceed sales projections and continued demand for diabetes drug Mounjaro. Clinical progress also continues in oncology, where a Phase 3 study evaluating Jaypirca in combination with other therapies met its primary goal of improving progression-free survival in blood cancer patients.

Investors will be watching the ongoing Phase 3 clinical trials for retatrutide, an investigational obesity drug that management projects could generate up to $25 billion in peak annual sales. Market participants are also keeping a close eye on the development of oral weight-loss treatment Foundayo, as well as the company's competitive standing against rival Novo Nordisk in the growing market for metabolic disorders.